Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation
- 7 December 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (2), 161-173
- https://doi.org/10.1093/europace/euq382
Abstract
Atrial fibrillation (AF) is the most common arrhythmia in clinical practise and its prevalence is increasing. Over the last 25 years, flecainide has been used extensively worldwide, and its capacity to reduce AF symptoms and provide long-term restoration of sinus rhythm (SR) has been well documented. The increased mortality seen in patients treated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) study, published in 1991, still deters many clinicians from using flecainide, denying many new AF patients a valuable treatment option. There is now a body of evidence that clearly demonstrates that flecainide has a favourable safety profile in AF patients without significant left ventricular disease or coronary heart disease. As a result of this evidence, flecainide is now recommended as one of the first-line treatment options for restoring and maintaining SR in patients with AF under current treatment guidelines. The objective of this article is to review the literature pertaining to the pharmacological characteristics, safety and efficacy of flecainide, and to place this drug in the context of current therapeutic management strategies for AF.Keywords
This publication has 116 references indexed in Scilit:
- Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark massJournal of Molecular and Cellular Cardiology, 2010
- Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of lifeEP Europace, 2010
- Secular trends in the prevalence of atrial fibrillation: The Framingham studyAmerican Heart Journal, 1996
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndromeAmerican Heart Journal, 1988
- FlecainideNew England Journal of Medicine, 1986
- Flecainide A Preliminary Review of its Pharmacodynamic Properties and Therapeutic EfficacyDrugs, 1985
- Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainideCardiovascular Research, 1983
- Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.Circulation, 1982
- Oral Flecainide Acetate for the Treatment of Ventricular ArrhythmiasNew England Journal of Medicine, 1981